Citius Pharmaceuticals Executes Definitive Agreement to Merge Wholly Owned Subsidiary with TenX Keane Acquisition to Form Publicly Listed Citius Oncology, Inc.
24 oct. 2023 07h30 HE
|
TenX Keane Acquisition
Citius Pharmaceuticals, Inc. to receive $675 million in equity of Citius Oncology, Inc. and retain approximately 90% majority control in publicly listed Citius Oncology, Inc. post transaction ...
Axogen, Inc. Announces Full Launch of Axoguard HA+ Nerve Protector™
05 sept. 2023 07h00 HE
|
Axogen, Inc.
ALACHUA, Fla. and TAMPA, Fla., Sept. 05, 2023 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve...
Axogen, Inc. Begins Processing Avance® Nerve Graft at New State-of-the-Art Facility in Dayton, Ohio
21 août 2023 07h00 HE
|
Axogen, Inc.
ALACHUA, Fla. and TAMPA, Fla., Aug. 21, 2023 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries,...
GLOBALLY RECOGNIZED ROSEN LAW FIRM Encourages ImmunityBio, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – IBRX
21 juil. 2023 22h25 HE
|
The Rosen Law Firm PA
NEW YORK, July 21, 2023 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of ImmunityBio, Inc. (NASDAQ: IBRX) between May 23, 2022 and May...
ROSEN, A HIGHLY RECOGNIZED LAW FIRM, Encourages Ampio Pharmaceuticals, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – AMPE
19 août 2022 10h51 HE
|
The Rosen Law Firm PA
NEW YORK, Aug. 19, 2022 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of the securities of...
Genmab to Submit Biologics License Application to U.S. Food and Drug Administration for Epcoritamab (DuoBody®-CD3xCD20) for the Treatment of Relapsed/Refractory Large B-Cell Lymphoma (LBCL)
30 juin 2022 14h24 HE
|
Genmab A/S
Company Announcement COPENHAGEN, Denmark; June 30, 2022 – Genmab A/S (Nasdaq: GMAB) today announced its intent to submit a biologics license application (BLA) to the U.S. Food and Drug...
Immunocore announces FDA approval of KIMMTRAK® (tebentafusp-tebn) for the treatment of unresectable or metastatic uveal melanoma
26 janv. 2022 07h00 HE
|
Immunocore Holdings Limited
Immunocore announces FDA approval of KIMMTRAK® (tebentafusp-tebn) for the treatment of unresectable or metastatic uveal melanomaKIMMTRAK is the first and only FDA approved therapy for the treatment of...
RVNC INVESTOR NOTICE: ROSEN, TRUSTED NATIONAL TRIAL COUNSEL, Encourages Revance Therapeutics, Inc. Investors with Losses to Secure Counsel Before Important Deadline in Securities Class Action – RVNC
16 déc. 2021 17h15 HE
|
The Rosen Law Firm PA
WHY: NEW YORK, Dec. 16, 2021 (GLOBE NEWSWIRE) -- Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of the securities of...
Pfizer und BioNTech leiten den Einreichungsprozess einer ergänzenden Biologics License Application bei der FDA für die Zulassung einer Auffrischungsimpfung mit COMIRNATY ® bei Personen ab 16 Jahren ein
25 août 2021 12h10 HE
|
BioNTech SE
Neue Daten der Phase-3-Studie zeigen, dass eine Auffrischungsimpfung (dritte Dosis) mit dem COVID-19-Impfstoff von Pfizer und BioNTech signifikante neutralisierende Antikörpertiter gegen SARS-CoV-2...
Pfizer and BioNTech Initiate Rolling Submission of Supplemental Biologics License Application to U.S. FDA for Booster Dose of COMIRNATY® in Individuals 16 and Older
25 août 2021 12h10 HE
|
BioNTech SE
New Phase 3 data show booster (third) dose of COMIRNATY induces significant SARS-CoV-2 neutralizing antibody titers and demonstrated a favorable safety and tolerability profileSARS-CoV-2 neutralizing...